This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Icon (ICLR)

Tipranks - Tipranks - Wed Jul 1, 4:38AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProMIS Neurosciences (PMN) and Icon (ICLR) with bullish sentiments.

End of Quarter Sale - 70% Off

ProMIS Neurosciences (PMN)

ProMIS Neurosciences received a Buy rating and a $39.75 price target from Cantor Fitzgerald analyst Pete Stavropoulos yesterday. The company’s shares closed last Monday at $10.75.

According to TipRanks.com, Stavropoulos is a 4-star analyst with an average return of 18.8% and a 49.2% success rate. Stavropoulos covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Vera Therapeutics, and Alector. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProMIS Neurosciences with a $33.55 average price target, implying a 214.9% upside from current levels. In a report issued on June 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.

See today’s best-performing stocks on TipRanks >>

Icon (ICLR)

Truist Financial analyst Jailendra Singh upgraded Icon to Buy yesterday and set a price target of $207.00. The company’s shares closed last Monday at $172.99.

According to TipRanks.com, Singh has 0 stars on 0-5 stars ranking scale with an average return of -7.1% and a 41.8% success rate. Singh covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Hinge Health, Inc. Class A, and Fortrea Holdings Inc. ;'>

Currently, the analyst consensus on Icon is a Moderate Buy with an average price target of $177.54, a 4.7% upside from current levels. In a report issued on June 25, RBC Capital also upgraded the stock to Buy with a $185.00 price target.

Read More on PMN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).